Please login to the form below

Not currently logged in
Email:
Password:

Burson-Marsteller appoint new EMEA health MD

Kate Hawker joins the agency from InforMed

Burson-Marsteller, Kate Hawker

Burson-Marsteller has appointed Kate Hawker as the new MD and chair of its EMEA and UK healthcare divisions.

“Kate is an excellent, and welcome, addition to Burson-Marsteller's outstanding group of EMEA practice chairs,” said Jeremy Galbraith, CEO of Burson-Marsteller EMEA.

“She brings the healthcare expertise and individual creativity that clients justifiably expect from a leading global agency and I am delighted she is joining us.”

She joins the agency after three years as business development director for InforMed, following the acquisition of her start-up medical communications company Medea.

During her 25-year career Hawker has directed pan-European and UK medical communications and PR programmes, having worked on campaigns for GSK, Baxter, Takeda, Boehringer-Ingelheim, Bristol Meyer Squibb, MSD and others.

She has also been a director and partner at Fleishman-Hillard, director at OCC and associate director for Shire Health International.


Commenting on her appointment, Hawker said: “I'm delighted to be joining Burson-Marsteller, an agency with a stand-out reputation for delivering integrated communications campaigns on a UK, EMEA and global level. I'm looking forward to working with a great team both in the UK and across EMEA.”

20th November 2012

From: Marketing, Healthcare

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...

Infographics